non-small cell lung cancer
-
AstraZeneca, Daiichi Cancer Drug’s Phase 3 Results Clouded by Toxicity Concerns
An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies disclosed few details about them.
-
At ASCO, BioNTech Shows Encouraging Data for Drug That Led to $200M Deal
BioNTech and OncoC4 reported Phase 1/2 data in non-small cell lung cancer for an immunotherapy called gotistobart. Earlier this year, the German company inked a deal to share in the development of the drug in various types of solid tumors.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen
Amgen’s Lumakras became the first FDA-approved drug that addresses the elusive KRAS mutation, but Mirati believes its newly approved therapy, Krazati, could be better. The small molecule’s features include the ability to penetrate into the brain, where it can address cancer that has spread to the central nervous system.
-
Biotech Firm Slashes 75% of Staff After FDA Rejects Drug for Rare Lung Cancer
In rejecting Spectrum Pharmaceuticals drug poziotinib, the FDA said the biotech needs to generate more data from another clinical trial. Instead, Spectrum is turning the company’s focus to commercializing its recently approved product for treating a common cancer complication.
-
AstraZeneca Drug Combo Lands FDA Nod for Non-Small Cell Lung Cancer
FDA approval of AstraZeneca’s Imjudo comes less than three weeks after the antibody won its first approval in liver cancer. Both regulatory decisions cover use of the drug in combination with another AstraZeneca immunotherapy, Imfinzi.
-
Report: Cancer deaths are down but pancreatic cancer is growing, racial disparities persist
Targeted drugs and immunotherapies are among the advances that contribute to declines in incidence and deaths from non-small cell lung cancer, according to the Annual Report to the Nation on the Status of Cancer. But the trends are on the rise for some other cancers and racial disparities persist, highlighting the need to better understand these differences.
-
CMS expands Medicare coverage for lung cancer screening
The Centers for Medicare and Medicaid Services announced the national coverage determination Thursday, expanding coverage for low-dose computed tomography for Medicare patients in line with current recommendations from the U.S. Preventative Services Task Force.
-
Takeda therapy gets speedy FDA nod for lung cancers with rare genetic signature
Takeda Pharmaceutical drug mobocertinib was approved by the FDA to treat non-small cell lung cancer in patients whose tumors carry a rare genetic signature. With the approval, Takeda can offer an oral alternative to a recently approved Johnson & Johnson drug that targets the same mutation but is given as an infusion.
-
ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more
The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Amgen lands first FDA approval for drug targeting elusive mutation in lung cancer
FDA approval of Amgen drug sotorasib (Lumakras) makes the small molecule the first compound authorized by the regulator for treating cancers characterized by a KRAS G12C mutation. Mutated KRAS proteins had long been regarded “undruggable” targets.
-
FDA approval of J&J drug is first for lung cancer with particular genetic mutation
Johnson & Johnson subsidiary Janssen was awarded approval for Rybrevant, the latest in a string of decisions for targeted therapies for non-small cell lung cancer. Rybrevant is the first approved targeted therapy addressing a subset of patients whose disease is characterized by a particular mutation to cancer protein EGFR.
-
Amgen announces ‘positive’ Phase II lung cancer results for cancer drug with hard-to-reach target
The company did not provide data, but said results for patients who received sotorasib at the 960mg dose were consistent with those seen in the Phase I portion of the Phase I/II study, which showed an overall response rate of 35.3%. ……
-
FDA green-lights second RET inhibitor, this time from Blueprint Medicines
The drug, Gavreto, or pralsetinib, won accelerated approval for RET fusion-positive non-small cell lung cancer, with or without prior therapy, while the FDA accepted the company’s approval application for the drug in two types of thyroid cancer. The approval follows the May nod for Eli Lilly’s Retevmo for all three indications.
-
Blueprint gets FDA priority review for competitor to newly approved Lilly cancer drug
Phase I/II data for pralsetinib in non-small cell lung cancer are the subject of a poster presented at the ASCO meeting. An expert noted the similarity between its clinical activity and that of Lilly’s drug, Retevmo. Both are RET inhibitors.
-
Spectrum’s shares slide after key pipeline drug fails in first cohort of study
Poziotinib did not show an improved response rate among previously treated non-small cell lung cancer patients with a specific genetic mutation, but additional cohorts in the Phase II study are ongoing.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
